Tag: nasdaq:thor

July 24, 2019

Synthorx Initiates Patient Dosing in Australia and Announces Clearance of IND in the U.S. for THOR-707

Synthorx (NASDAQ:THOR) has announced it has begun its  Phase 1/2 clinical trial of THOR-707 in Australia as well as receiving...
December 31, 2018

4 Life Science IPOs in December

December brought four life science IPOs on the NASDAQ, giving investors new opportunities to enter the market.
December 16, 2018

5 Top Weekly NASDAQ Biotech Stocks: Innovate Leads the Pack

Innovate Biopharmaceuticals, Aridis Pharmaceuticals, Imprimis Pharmaceuticals, Achaogen and SynthoRx were last week's top gainers.
December 13, 2018

Synthorx Announces Closing of Initial Public Offering

Synthorx (Nasdaq:THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for...